[1]
|
Tuasha, N. and Petros, B. (2020) Heterogeneity of Tumors in Breast Cancer: Implications and Prospects for Prognosis and Therapeutics. Scientifica, 2020, Article ID: 4736091. https://doi.org/10.1155/2020/4736091
|
[2]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. https://doi.org/10.3322/caac.21708
|
[3]
|
Sarrazin, S., Lamanna, W.C. and Esko, J.D. (2011) Heparan Sulfate Pro-teoglycans. Cold Spring Harbor Perspectives in Biology, 3, Article ID: a004952. https://doi.org/10.1101/cshperspect.a004952
|
[4]
|
Rangarajan, S., Richter, J.R., Richter, R.P., Bandari, S.K., Tripathi, K., Vlodavsky, I. and Sanderson, R.D. (2020) Heparanase-Enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression. Journal of Histochemistry & Cytochemistry, 68, 823-840. https://doi.org/10.1369/0022155420937087
|
[5]
|
Gharbaran, R. (2015) Advances in the Molecular Functions of Syndecan-1 (SDC1/CD138) in the Pathogenesis of Malignancies. Critical Reviews in Oncology/Hematology, 94, 1-17. https://doi.org/10.1016/j.critrevonc.2014.12.003
|
[6]
|
Parimon, T., Brauer, R., Schlesinger, S.Y., Xie, T., Jiang, D., Ge, L., Huang, Y., Birkland, T.P., Parks, W.C., Habiel, D.M., Hogaboam, C.M., Gharib, S.A., Deng, N., Liu, Z. and Chen, P. (2018) Syndecan-1 Controls Lung Tumorigenesis by Regulating miRNAs Packaged in Exosomes. The American Journal of Pathology, 188, 1094-1103.
https://doi.org/10.1016/j.ajpath.2017.12.009
|
[7]
|
Liu, W., Wang, Y., Zheng, J., Song, D., Zheng, S., Ren, L., Wang, Y., Yao, Y., Wang, Y., Liu, Y., Bai, R., Dong, J. and Liu, T. (2019) Syndecan-1 as an Independent Risk Factor for the Incidence of Adverse Cardiovascular Events in Patients Having Stage C and D Heart Failure with Non-Ischemic Dilated Cardiomyopathy. Clinica Chimica Acta, 490, 63-68. https://doi.org/10.1016/j.cca.2018.12.022
|
[8]
|
Jaiswal, A.K., Sadasivam, M., Archer, N.K., Miller, R.J., Dillen, C.A., Ravipati, A., Park, P.W., Chakravarti, S., Miller, L.S. and Hamad, A.R.A. (2018) Syndecan-1 Regulates Psoriasiform Dermatitis by Controlling Homeostasis of IL-17- Producing γδ T Cells. The Journal of Immunology, 201, 1651-1661. https://doi.org/10.4049/jimmunol.1800104
|
[9]
|
Bernfield, M., Götte, M., Park, P.W., Reizes, O., Fitzgerald, M.L., Lincecum, J. and Zako, M. (1999) Functions of Cell Surface Heparan Sulfate Proteoglycans. Annual review of biochemistry, 68, 729-777.
https://doi.org/10.1146/annurev.biochem.68.1.729
|
[10]
|
De Rossi, G. and Whiteford, J.R. (2013) Novel Insight into the Biological Functions of Syndecan Ectodomain Core Proteins. Biofactors, 39, 374-382. https://doi.org/10.1002/biof.1104
|
[11]
|
Maday, S., Anderson, E., Chang, H.C., Shorter, J., Satoh, A., Sfakianos, J., Fölsch, H., Anderson, J.M., Walther, Z. and Mellman, I. (2008) A PDZ-Binding Motif Controls Basolateral Targeting of Syndecan-1 along the Biosynthetic Pathway in Polarized Epithelial Cells. Traffic, 9, 1915-1924. https://doi.org/10.1111/j.1600-0854.2008.00805.x
|
[12]
|
Jung, O., Trapp-Stamborski, V., Purushothaman, A., Jin, H., Wang, H., Sanderson, R.D. and Rapraeger, A.C. (2016) Heparanase-Induced Shedding of Syndecan-1/CD138 in Myeloma and Endothelial Cells Activates VEGFR2 and an Invasive Phenotype: Prevention by Novel Synstatins. Oncogenesis, 5, e202. https://doi.org/10.1038/oncsis.2016.5
|
[13]
|
Chakravarti, R., Sapountzi, V. and Adams, J.C. (2005) Functional Role of Syndecan-1 Cytoplasmic V Region in Lamellipodial Spreading, Actin Bundling, and Cell Migration. Molecular Biology of the Cell, 16, 3678-3691.
https://doi.org/10.1091/mbc.e04-10-0907
|
[14]
|
Alexopoulou, A.N., Multhaupt, H.A. and Couchman, J.R. (2007) Syndecans in Wound Healing, Inflammation and Vascular Biology. The International Journal of Biochemistry & Cell Biology, 39, 505-528.
https://doi.org/10.1016/j.biocel.2006.10.014
|
[15]
|
Zhang, L., David, G. and Esko, J.D. (1995) Repetitive Ser-Gly Sequences Enhance Heparan Sulfate Assembly in Proteoglycans. Journal of Biological Chemistry, 270, 27127-27135. https://doi.org/10.1074/jbc.270.45.27127
|
[16]
|
Mulloy, B., Lever, R. and Page, C.P. (2017) Mast Cell Glycosaminoglycans. Glycoconjugate Journal, 34, 351-361.
https://doi.org/10.1007/s10719-016-9749-0
|
[17]
|
Bertrand, J. and Bollmann, M. (2019) Soluble Syndecans: Bi-omarkers for Diseases and Therapeutic Options. British Journal of Pharmacology, 176, 67-81. https://doi.org/10.1111/bph.14397
|
[18]
|
Derksen, P.W., Keehnen, R.M., Evers, L.M., Van Oers, M.H., Spaargaren, M. and Pals, S.T. (2002) Cell Surface Proteoglycan Syndecan-1 Mediates Hepatocyte Growth Factor Binding and Promotes Met Signaling in Multiple Myeloma. Blood, 99, 1405-1410. https://doi.org/10.1182/blood.V99.4.1405
|
[19]
|
Moreaux, J., Sprynski, A.C., Dillon, S.R., Mahtouk, K., Jourdan, M., Ythier, A., Moine, P., Robert, N., Jourdan, E., Rossi, J.F. and Klein, B. (2009) APRIL and TACI Interact with Syndecan-1 on the Surface of Multiple Myeloma Cells to form an Essential Survival Loop. European Journal of Hae-matology, 83, 119-129.
https://doi.org/10.1111/j.1600-0609.2009.01262.x
|
[20]
|
Khotskaya, Y.B., Dai, Y., Ritchie, J.P., MacLeod, V., Yang, Y., Zinn, K. and Sanderson, R.D. (2009) Syndecan-1 Is Required for Robust Growth, Vascularization, and Me-tastasis of Myeloma Tumors in Vivo. Journal of Biological Chemistry, 284, 26085-26095. https://doi.org/10.1074/jbc.M109.018473
|
[21]
|
Wu, Y.H., Yang, C.Y., Chien, W.L., Lin, K.I. and Lai, M.Z. (2012) Removal of Syndecan-1 Promotes TRAIL-Induced Apoptosis in Myeloma Cells. The Journal of Immunology, 188, 2914-2921. https://doi.org/10.4049/jimmunol.1102065
|
[22]
|
Purushothaman, A., Uyama, T., Kobayashi, F., Yamada, S., Sugahara, K., Rapraeger, A.C. and Sanderson, R.D. (2010) Heparanase-Enhanced Shedding of Syndecan-1 by Myeloma Cells Promotes Endothelial Invasion and Angiogenesis. Blood, 115, 2449-2457. https://doi.org/10.1182/blood-2009-07-234757
|
[23]
|
Francescone, R.A., Scully, S., Faibish, M., Taylor, S.L., Oh, D., Moral, L., Yan, W., Bentley, B. and Shao, R. (2011) Role of YKL-40 in the Angiogenesis, Radioresistance, and Progression of Glioblastoma. Journal of Biological Chemistry, 286, 15332-15343. https://doi.org/10.1074/jbc.M110.212514
|
[24]
|
Yoshida, Y., Kurokawa, T., Nishikawa, Y., Orisa, M., Kleinman, H.K. and Kotsuji, F. (2008) Laminin-1-Derived Scrambled Peptide AG73T Disaggregates Laminin-1-Induced Ovarian Cancer Cell Spheroids and Improves the Efficacy of Cisplatin. International Journal of Oncology, 32, 673-681. https://doi.org/10.3892/ijo.32.3.673
|
[25]
|
Ramani, V.C. and Sanderson, R.D. (2014) Chemotherapy Stimulates Syndecan-1 Shedding: A Potentially Negative Effect of Treatment That May Promote Tumor Relapse. Matrix Biology, 35, 215-222.
https://doi.org/10.1016/j.matbio.2013.10.005
|
[26]
|
Ramani, V.C., Yang, Y., Ren, Y., Nan, L. and Sanderson, R.D. (2011) Heparanase Plays a Dual Role in Driving Hepatocyte Growth Factor (HGF) Signaling by Enhancing HGF Ex-pression and Activity. Journal of Biological Chemistry, 286, 6490-6499. https://doi.org/10.1074/jbc.M110.183277
|
[27]
|
Wang, X., Zuo, D., Chen, Y., Li, W., Liu, R., He, Y., Ren, L., Zhou, L., Deng, T., Wang, X., Ying, G. and Ba, Y. (2014) Shed Syndecan-1 Is Involved in Chemotherapy Resistance via the EGFR Pathway in Colorectal Cancer. British Journal of Cancer, 111, 1965-1976. https://doi.org/10.1038/bjc.2014.493
|
[28]
|
Yu, L., Xu, H., Zhang, S., Chen, J. and Yu, Z. (2020) SDC1 Promotes Cisplatin Resistance in Hepatic Carcinoma Cells via PI3K-AKT Pathway. Human Cell, 33, 721-729. https://doi.org/10.1007/s13577-020-00362-6
|
[29]
|
Alexander, C.M., Reichsman, F., Hinkes, M.T., Lincecum, J., Becker, K.A., Cumberledge, S. and Bernfield, M. (2000) Syndecan-1 Is Required for Wnt-1-Induced Mammary Tumorigenesis in Mice. Nature Genetics, 25, 329-332.
https://doi.org/10.1038/77108
|
[30]
|
Maeda, T., Desouky, J. and Friedl, A. (2006) Syndecan-1 Expression by Stromal Fibroblasts Promotes Breast Carcinoma Growth in Vivo and Stimulates Tumor Angiogenesis. Oncogene, 25, 1408-1412.
https://doi.org/10.1038/sj.onc.1209168
|
[31]
|
Sun, H., Berquin, I.M., Owens, R.T., O’Flaherty, J.T. and Edwards, I.J. (2008) Peroxisome Proliferator-Activated Receptor Gamma-Mediated Up-Regulation of Syndecan-1 by n-3 Fatty Acids Promotes Apoptosis of Human Breast Cancer Cells. Cancer Research, 68, 2912-2919. https://doi.org/10.1158/0008-5472.CAN-07-2305
|
[32]
|
Vuoriluoto, K., Högnäs, G., Meller, P., Lehti, K. and Ivaska, J. (2011) Syndecan-1 and -4 Differentially Regulate Oncogenic K-ras Dependent Cell Invasion into Collagen through α2β1 Integrin and MT1-MMP. Matrix Biology, 30, 207-217. https://doi.org/10.1016/j.matbio.2011.03.003
|
[33]
|
Götte, M., Kersting, C., Ruggiero, M., Tio, J., Tulusan, A.H., Kiesel, L. and Wülfing, P. (2006) Predictive Value of Syndecan-1 Expression for the Response to Neoadjuvant Chem-otherapy of Primary Breast Cancer. Anticancer Research, 26, 621-627.
|
[34]
|
Pradella, D., Naro, C., Sette, C. and Ghigna, C. (2017) EMT and Stemness: Flexible Processes Tuned by Alternative Splicing in Development and Cancer Progression. Molecular Cancer, 16, Article No. 8.
https://doi.org/10.1186/s12943-016-0579-2
|
[35]
|
Orecchia, P., Conte, R., Balza, E., Petretto, A., Mauri, P., Mingari, M.C. and Carnemolla, B. (2013) A Novel Human Anti-Syndecan-1 Antibody Inhibits Vascular Maturation and Tumour Growth in Melanoma. European Journal of Cancer, 49, 2022-2033. https://doi.org/10.1016/j.ejca.2012.12.019
|
[36]
|
Macaulay, V.M., O’Byrne, K.J., Saunders, M.P., Braybrooke, J.P., Long, L., Gleeson, F., Mason, C.S., Harris, A.L., Brown, P. and Talbot, D.C. (1999) Phase I Study of Intrapleural Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in the Treatment of Malignant Pleural Effusions. Clinical Cancer Research, 5, 513-520.
|
[37]
|
Remacle, A.G., Golubkov, V.S., Shiryaev, S.A., Dahl, R., Stebbins, J.L., Chernov, A.V., Cheltsov, A.V., Pellecchia, M. and Strongin, A.Y. (2012) Novel MT1-MMP Small-Molecule Inhibitors Based on Insights into Hemopexin Domain Function in Tumor Growth. Cancer Research, 72, 2339-2349. https://doi.org/10.1158/0008-5472.CAN-11-4149
|
[38]
|
Nguyen, T.L., Grizzle, W.E., Zhang, K., Hameed, O., Siegal, G.P. and Wei, S. (2013) Syndecan-1 Overexpression Is Associated with Nonluminal Subtypes and Poor Prognosis in Advanced Breast Cancer. American Journal of Clinical Pathology, 140, 468-474. https://doi.org/10.1309/AJCPZ1D8CALHDXCJ
|